Sagesse Bio is an early stage pharmaceutical company utilizing RNAi technology to accelerate the clinical development of novel solutions to destroy or remodel undesirable pockets of fat. The company's lead compound, SGY-101, is IND-enabled and currently in Phase II clinical trials for other indications.
Sagesse Bio will promptly begin clinical evaluation of SGY-101 with comprehensive scientific and technical support from Sirnaomics which specializes in the development of RNAi technology. Initial indications of interest include body contouring and fat reduction. The strategic goal of Sagesse Bio is to become the leading provider of therapeutic solutions for targeted fat reduction in both medical dermatology and aesthetic medicine.
Company Details
- Employees
- 1
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.sagessebio.com
Sagesse Bio Questions
Sagesse Bio's website is http://www.sagessebio.com
Sagesse Bio's LinkedIn profile is https://www.linkedin.com/company/sagesse-bio
Sagesse Bio has
1 employees.
View email and phone details for 1
employees at Sagesse Bio.
Sagesse Bio's industry is
Biotechnology Research
Sagesse Bio's top competitors are
Nanoscope Therapeutics Inc.,
Clexio Biosciences,
Alpenglow Biosciences,
Melanyze,
Rubedo Life Sciences,
Union Therapeutics A/s,
Opthea,
Yaso Therapeutics Inc.,
Concerto Biosciences,
Reinvigoron Theratech Inc..
Sagesse Bio's categories are Biotechnology Research
Sagesse Bio's founding year is 2024
